Medical News

RSS

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.

11 Aug 2010

Progestins have tumor-stage specific effects that determine promotion, suppression: Study

Progestins are used in hormone replacement therapies to counteract the negative effects of estrogen on the uterus and reduce the risk of uterine cancer. However, evidence in recent studies and clinical trials has demonstrated that progestins increase the risk of breast cancer. Now, University of Missouri researchers have compared four types of progestins used in hormone replacement therapies and found significantly different outcomes on the progression of breast cancer in an animal model depending on the type of progestins used.

11 Aug 2010

Mindfit brain fitness program helps frail seniors walk faster

Computerized brain fitness programs are known to help seniors improve their memory and focus. Now, a study led by researchers at Albert Einstein College of Medicine of Yeshiva University has found preliminary evidence that such programs may help frail seniors walk faster, potentially preventing disability and improving quality of life. Results appear in the July 19 online edition of the Journal of Gerontology.

11 Aug 2010

Cardiovascular Systems fourth-quarter revenue increases 15% to $18.0 million

Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal fourth quarter and year ended June 30, 2010.

11 Aug 2010

Scientists develop new method to enable drug release inside cancer cells

Scientists from UCLA's California NanoSystems Institute and Korea's Yonsei University have developed an innovative method that enables nanomachines to release drugs inside living cancer cells when activated remotely by an oscillating magnetic field.The new system - the first to utilize a class of porous nanomaterials driven by a magnetic core - has the potential to improve both targeted drug-delivery and magnetic resonance imaging in the treatment of cancer and other diseases.

11 Aug 2010

State News: Ex-Anthem Blue Cross president speaks out; Clinics to fill in N.M. primary care gap

The Los Angeles Times: "The abrupt resignation last month of Anthem Blue Cross' president is offering a glimpse of an internal struggle that has roiled California's largest for-profit health insurer for months. Leslie Margolin was the public face of Anthem this year when it sought to raise individual insurance rates as much as 39%.

11 Aug 2010

Study suggests zinc supplementation may reduce pneumonia risk

A high proportion of nursing facility residents were found to have low serum (blood) zinc concentrations during an observational study funded by the Agricultural Research Service (ARS) and the National Institute of Aging. The scientists found that those with normal blood zinc concentrations were about 50 percent less likely to develop pneumonia than those with low concentrations.

11 Aug 2010

Noven enters agreement to acquire global rights to ADHD drug Daytrana from Shire

Noven Pharmaceuticals, Inc. today announced that it has entered into a Product and Trademark Acquisition Agreement with affiliates of Shire plc pursuant to which Noven will acquire global rights to Daytrana® (methylphenidate transdermal system) from Shire.

11 Aug 2010

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an exclusive agreement to leverage the translational research expertise of Dr. Jason Chesney, Associate Professor, Department of Medicine at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center), to identify new clinical candidates for the prevention and treatment of cancers against two key cancer metabolic targets.

11 Aug 2010

Study reveals no evidence of link between bisphosphonates to esophageal cancer risk

Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.

11 Aug 2010

Opinions: HIV prevention research; Foreign aid; Sanitation; Aid, self-reliance

"Microbicides, vaccines and other new approaches will one day join proven HIV-prevention strategies, including condoms, male circumcision and clean needles. How soon that day comes will depend on whether funders and the scientific community can develop the more collaborative approaches to HIV prevention research needed to address this fast-moving epidemic," Global HIV Vaccine Enterprise leaders Alan Bernstein, executive director, and Peter Piot, chair, write in a Globe and Mail opinion piece.

11 Aug 2010

Today's Opinions and Editorials: Bringing down health care costs; More on the Medicare trustees report

Short of transforming the medical payment system, can we bring down health care costs by feasible fixes? Yes, by reducing the number of services that must be covered by every insurance policy and requiring higher copayments for patients using the highest cost providers (Robert Pozen, 8/10).

11 Aug 2010

‘Decriminalize’ but not ‘Legalize’ drug abuse says Australian Sex party

Professor Paul Wilson, an Australian criminologist revealed that illegal drug use in Australia costs the nation $3.8 billion every year. Australian Sex Party however claims personal drug use should be decriminalized and drug abusers sent for rehabilitation instead of imprisonment.

10 Aug 2010

Telephone monitoring can save heart failure patients: Study

Chronic heart failure needs constant care and regular monitoring. Now research says remote monitoring, either over the phone or using wireless technology, helps people with heart failure live longer and stay out of hospital.

10 Aug 2010

Breath test to detect cancer: Study

According to researchers cancer may soon be detectable using a breath test. They are now developing sensors that can detect chemical markers of lung, breast, bowel and prostate cancer in a person's breath. The new portable device has been purported as an “electronic nose” that can detect early cancers. As a cancer grows, the surface of the cells emits chemicals. The research found that sensors – involving gold nanoparticles – could be used to detect these chemicals in the breath.

10 Aug 2010

FDA clears RyMed's InVision-Plus CS needleless IV connector

RyMed Technologies announced today that it has received FDA 510(k) clearance for its newest IV connector, InVision-Plus® CS™ with Chlorhexidine-Silver Ion Engineering.

10 Aug 2010

Atrium awarded 3-year national contract from Premier for surgical mesh products

Atrium Medical Corporation, pioneering advancements in biological, mechanical and therapeutic solutions for soft tissue reinforcement, is proud to announce that the company was awarded a three-year national contract from Premier Purchasing Partners L.P., the group purchasing organization of Premier, Inc. (Charlotte, NC).

10 Aug 2010

CADTH Review Panel releases recommendations for Biologic Response Modifier Agents for Adults with RA

The Canadian Agency for Drugs and Technologies in Health's (CADTH) Therapeutic Review Panel released last week their recommendations for Biologic Response Modifier Agents for Adults with Rheumatoid Arthritis (RA).

10 Aug 2010

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Research at the Babraham Institute, investigating how white blood cells known as B cells develop, has revealed that genes from the Phosphatidylinositol 3-kinase family of enzymes are critical in enabling the B cells to produce antibodies in the spleen and lymph nodes.

10 Aug 2010

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Vertex Pharmaceuticals Incorporated today announced results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus (HCV) was undetectable at weeks 4 and 12 of treatment (extended rapid viral response or eRVR).

10 Aug 2010

Medical News

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Progestins have tumor-stage specific effects that determine promotion, suppression: Study

Mindfit brain fitness program helps frail seniors walk faster

Cardiovascular Systems fourth-quarter revenue increases 15% to $18.0 million

Scientists develop new method to enable drug release inside cancer cells

State News: Ex-Anthem Blue Cross president speaks out; Clinics to fill in N.M. primary care gap

Study suggests zinc supplementation may reduce pneumonia risk

Noven enters agreement to acquire global rights to ADHD drug Daytrana from Shire

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Study reveals no evidence of link between bisphosphonates to esophageal cancer risk

Opinions: HIV prevention research; Foreign aid; Sanitation; Aid, self-reliance

Today's Opinions and Editorials: Bringing down health care costs; More on the Medicare trustees report

‘Decriminalize’ but not ‘Legalize’ drug abuse says Australian Sex party

Telephone monitoring can save heart failure patients: Study

Breath test to detect cancer: Study

FDA clears RyMed's InVision-Plus CS needleless IV connector

Atrium awarded 3-year national contract from Premier for surgical mesh products

CADTH Review Panel releases recommendations for Biologic Response Modifier Agents for Adults with RA

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Squid™ Full Range Pipette: Reduce pipette changes, bench clutter, and calibration burden

Advancing Menopause Care: Non-Hormonal Treatments for Vasomotor Symptoms

Building quality into drug development for safer, faster medicines

Latest News